Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells

Clinical Cancer Research

Volumn 10, Issue 20, 2004, Pages 7031-7042

  Mondesire, Wallace H ^a   Jian, Weiguo ^a   Zhang, Haixia ^a   Ensor, Joe ^a   Hung, Mien Chie ^a   Mills, Gordon B ^a   Meric Bernstam, Funda ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; NAVELBINE; PACLITAXEL; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; EMBRYO; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MODEL; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR VOLUME; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROTEIN KINASES; SIROLIMUS; TUMOR CELLS, CULTURED;

EID: 6044259204     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0361     Document Type: Article

References (42)

1. Vezina C, Kudelski A, Sehgal S. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975;28:721-6.
2. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981;8:63-87.
3. Meric F, Hunt K. Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther 2002;1:971-9.
4. Inoki K, Li Y, Zhu T, Wu J, Guan K. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:648-57.
5. Sekulic A, Hudson C, Homme J, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504-13.
6. Scott P, Lawrence J Jr. Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes. J Biol Chem 1998;273:34496-501.
7. 2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 2002;277:17657-62.
8. Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 2000;275:8027-31.
9. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003;17:575-88.
10. Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM. Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells. J Cell Biol 2002;158:165-74.
11. Noh W, Mondesire W, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004;10:1013-23.
12. 1 arrest and determine the cellular response to rapamycin. Cancer Res 2001;61:3373-81.
13. Hosoi H, Dilling M, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-94.
14. Eng C, Sehgal S, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984;37:1231-7.
15. Geoerger B, Kerr K, Tang C, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001;61:1527-32.
16. Xu Q, Simpson S, Scialla T, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972-80.
17. Shi Y, Frankel A, Radvanyi L, et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995;55:1982-8.
18. Chou T, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Page R. Principles of chemotherapy. In: Pazdur, R, Hoskins, WJ, Coia, LR, Wagman, LD, editors. Cancer management: a multidisciplinary approach, 5th ed. Melville, NY: PRR, Inc.; 2001.
20. Soldani C, Scovassi A. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321-8.
21. Yu D, Liu B, Tan M, et al. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13:1359-65.
22. Meric F, Hung M, Hortobagyi G, Hunt K. HER2/neu in the management of invasive breast cancer. J Am Coll Surg 2002;194:488-501.
23. 424 via multiple signaling pathways in mitosis. Oncogene 2003;22:484-97.
24. Magne N, Fischel JL, Dubreuil A, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002;86:1518-23.
25. Lee S, Yang W, Lan KH, et al. Enhanced sensitization to Taxol-induced apoptosis by Herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002;62:5703-10.
26. 1 apoptosis. Apoptosis 1997;2:463-70.
27. Neshat M, Mellinghoff I, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001;98:10314-9.
28. Podsypanina K, Lee R, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 2001;98:10320-5.
29. Mills G, Lu Y, Kohn E. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:10031-3.
30. Tanaka M, Koul D, Davies M, et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000;19:5406-12.
31. Grünwald V, DeGraffenried L, Russel D, et al. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002;62:6141-5.
32. Wendel H, De Stanchina E, Fridman J, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (Lond) 2004;428:332-7.
33. Wan X, Helman L. Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia 2002;4:400-8.
34. Harada H, Andersen J, Mann M, Terada N, Korsmeyer S. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001;98:9666-70.
35. Polunovsky V, Rosenwald I, Tan A, et al. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol Cell Biol 1996;16:6573-81.
36. Li S, Sonenberg N, Gingras A, et al. Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol 2002;22:2853-61.
37. Tee A, Proud C. Caspase cleavage of initiation factor 4E-binding protein 1 yields a dominant inhibitor of cap-dependent translation and reveals a novel regulatory motif. Mol Cell Biol 2002;22:1674-83.
38. 2-terminal kinase (JNK/SAPK). J Biol Chem 1998;273:28253-60.
39. Okano J, Rustgi A. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem 2001;276:19555-64.
40. Wang T, Popp D, Wang H, et al. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem 1999;274:8208-16.
41. Sanchez-Perez I, Murguia J, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998;16:533-40.
42. Cip1. Mol Cell 2003;11:1491-501.